ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

(MedPage Today) — SAN ANTONIO — The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118963

Author :

Publish date : 2025-12-11 20:07:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

FDA Proposes Allowing New Sunscreen Ingredient

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

Related Posts

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

FDA Proposes Allowing New Sunscreen Ingredient

FDA OKs First At-Home Brain Stim Device for Depression

Expand Labeling for Testosterone Replacement Therapy, FDA Panel Says

Incretin-Based Meds May Modestly Raise Biliary Risk in T2D

RFK Jr. Tops This Year’s Shkreli Awards

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

FDA Proposes Allowing New Sunscreen Ingredient

FDA OKs First At-Home Brain Stim Device for Depression

Expand Labeling for Testosterone Replacement Therapy, FDA Panel Says

Incretin-Based Meds May Modestly Raise Biliary Risk in T2D

RFK Jr. Tops This Year’s Shkreli Awards

Should Congress Intervene in the Newborn Hep B Vaccine Controversy?

Categories

Archives